The novel therapeutic belumosudil (BEL) was recently approved for use in patients with chronic graft-versus-host disease (cGVHD). Researchers at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, set out to determine whether BEL could affect the therapeutic levels of the current standard prophylaxis for cGVHD, tacrolimus (TAC) and sirolimus (SIRO), either in combination with one another or alone. ...
2022 ASH Annual Meeting & Exposition - Focus on GVHD
The 64th American Society of Hematology Annual Meeting and Exposition took place December 10-13 in New Orleans, Louisiana. This year’s meeting featured plenary lectures, expert sessions, poster presentations, and much more. Find highlights from the sessions that are most relevant to oncology nurses, including those with a focus on the latest treatment strategies for graft-versus-host disease.
Advertisement
GVHD prophylaxis with itacitinib plus tacrolimus/sirolimus was safe and well-tolerated after transplant.
No GVHD was reported in patients with CD30-positive lymphoma who received CD30.CAR EBVSTs.
GVHD prophylaxis with posttransplant cyclophosphamide plus tacrolimus was better than tacrolimus alone for allogeneic HCT.
Extensive chronic GVHD occurred in 15% of patients with ALL within 2 years of undergoing allogeneic HSCT.
Patients receiving allogeneic HSCT face an average of $1 million in transplant-related costs throughout their lifetimes.
Belumosudil combination therapy in a real-world setting “appears safe, tolerable, and effective” for chronic GVHD.
Fludarabine plus busulfan led to lower rates of grade III-IV acute GVHD than cyclophosphamide plus busulfan.
No moderate-to-severe chronic GVHD occurred in patients with high-risk hematologic malignancies who received Orca-Q.
Around one-third of patients with TP53-mutated acute leukemias or MDS who underwent HSCT developed chronic GVHD.
Donor-derived, CD7-directed, CAR T-cell therapy had “encouraging activity” but led to reversible GVHD in 40% of patients.
No GVHD exacerbations occurred with a BCMA-directed CAR-T in patients with multiple myeloma.
Frailty is strongly associated with worse survival outcomes in patients with chronic graft-versus-host disease (GVHD).
No graft-versus-host disease (GVHD) occurred in patients with multiple myeloma (MM) who received allogeneic CAR-T therapy.
Donor age and type can significantly affect the outcomes of patients who undergo hematopoietic cell transplantation.
Around 25% of patients with high-risk MDS or AML who received venetoclax plus azacitidine maintenance developed chronic GVHD.
Belumosudil can impact the pharmacokinetics of tacrolimus and sirolimus, which is important for dosing considerations.
GVHD was only reported in one patient who received veto cells plus haploidentical T-cell-depleted HSCT.
Patients who received a triplet regimen as GVHD prophylaxis after HSCT had favorable outcomes.
A new method of peripheral blood stem cell hematopoietic cell transplantation led to a 1-year chronic GVHD rate of 11%.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.